Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Safety and pharmacokinetics of veliparib extended-release in patients with advanced solid tumors: a phase I study.

Werner TL, Sachdev J, Swisher EM, Gutierrez M, Kittaneh M, Stein MN, Xiong H, Dunbar M, Sullivan D, Komarnitsky P, McKee M, Tan AR.

Cancer Med. 2018 Jun;7(6):2360-2369. doi: 10.1002/cam4.1488. Epub 2018 May 7.

2.

A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours.

Berlin J, Ramanathan RK, Strickler JH, Subramaniam DS, Marshall J, Kang YK, Hetman R, Dudley MW, Zeng J, Nickner C, Xiong H, Komarnitsky P, Shepherd SP, Hurwitz H, Lenz HJ.

Br J Cancer. 2018 Apr;118(7):938-946. doi: 10.1038/s41416-018-0003-3. Epub 2018 Mar 12.

3.

Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer.

Nishio S, Takekuma M, Takeuchi S, Kawano K, Tsuda N, Tasaki K, Takahashi N, Abe M, Tanaka A, Nagasawa T, Shoji T, Xiong H, Nuthalapati S, Leahy T, Hashiba H, Kiriyama T, Komarnitsky P, Hirashima Y, Ushijima K.

Cancer Sci. 2017 Nov;108(11):2213-2220. doi: 10.1111/cas.13381. Epub 2017 Sep 18.

4.

Phase 1 dose-escalation study of single-agent veliparib in Japanese patients with advanced solid tumors.

Nishikawa T, Matsumoto K, Tamura K, Yoshida H, Imai Y, Miyasaka A, Onoe T, Yamaguchi S, Shimizu C, Yonemori K, Shimoi T, Yunokawa M, Xiong H, Nuthalapati S, Hashiba H, Kiriyama T, Leahy T, Komarnitsky P, Fujiwara K.

Cancer Sci. 2017 Sep;108(9):1834-1842. doi: 10.1111/cas.13307. Epub 2017 Aug 5.

5.

Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study.

Czito BG, Deming DA, Jameson GS, Mulcahy MF, Vaghefi H, Dudley MW, Holen KD, DeLuca A, Mittapalli RK, Munasinghe W, He L, Zalcberg JR, Ngan SY, Komarnitsky P, Michael M.

Lancet Gastroenterol Hepatol. 2017 Jun;2(6):418-426. doi: 10.1016/S2468-1253(17)30012-2. Epub 2017 Mar 27.

PMID:
28497757
6.

A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma.

Mok TS, Geater SL, Su WC, Tan EH, Yang JC, Chang GC, Han M, Komarnitsky P, Payumo F, Garrus JE, Close S, Park K.

J Thorac Oncol. 2016 Oct;11(10):1736-44. doi: 10.1016/j.jtho.2016.05.038. Epub 2016 Jul 21.

7.

Cyclophosphamide and tucotuzumab (huKS-IL2) following first-line chemotherapy in responding patients with extensive-disease small-cell lung cancer.

Gladkov O, Ramlau R, Serwatowski P, Milanowski J, Tomeczko J, Komarnitsky PB, Kramer D, Krzakowski MJ.

Anticancer Drugs. 2015 Nov;26(10):1061-8. doi: 10.1097/CAD.0000000000000281.

PMID:
26295868
8.

A pharmacodynamic/pharmacokinetic study of ficlatuzumab in patients with advanced solid tumors and liver metastases.

Tabernero J, Elez ME, Herranz M, Rico I, Prudkin L, Andreu J, Mateos J, Carreras MJ, Han M, Gifford J, Credi M, Yin W, Agarwal S, Komarnitsky P, Baselga J.

Clin Cancer Res. 2014 May 15;20(10):2793-804. doi: 10.1158/1078-0432.CCR-13-1837. Epub 2014 Mar 14.

9.

A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors.

Connor JP, Cristea MC, Lewis NL, Lewis LD, Komarnitsky PB, Mattiacci MR, Felder M, Stewart S, Harter J, Henslee-Downey J, Kramer D, Neugebauer R, Stupp R.

BMC Cancer. 2013 Jan 15;13:20. doi: 10.1186/1471-2407-13-20.

10.

Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin.

Jones B, Komarnitsky P, Miller GT, Amedio J, Wallner BP.

Anticancer Drugs. 2012 Feb;23(2):173-84. doi: 10.1097/CAD.0b013e32834d73a6.

PMID:
22027537
11.

A phase I clinical trial of darinaparsin in patients with refractory solid tumors.

Tsimberidou AM, Camacho LH, Verstovsek S, Ng C, Hong DS, Uehara CK, Gutierrez C, Daring S, Stevens J, Komarnitsky PB, Schwartz B, Kurzrock R.

Clin Cancer Res. 2009 Jul 15;15(14):4769-76. doi: 10.1158/1078-0432.CCR-08-2984. Epub 2009 Jul 7.

12.

A novel arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1-overexpressing cell lines.

Diaz Z, Mann KK, Marcoux S, Kourelis M, Colombo M, Komarnitsky PB, Miller WH Jr.

Leukemia. 2008 Oct;22(10):1853-63. doi: 10.1038/leu.2008.194. Epub 2008 Jul 17. Erratum in: Leukemia. 2009 Feb;23(2):431.

PMID:
18633430
13.

The essential interaction between yeast mRNA capping enzyme subunits is not required for triphosphatase function in vivo.

Takase Y, Takagi T, Komarnitsky PB, Buratowski S.

Mol Cell Biol. 2000 Dec;20(24):9307-16.

14.
15.
16.

Histone-like TAFs are essential for transcription in vivo.

Michel B, Komarnitsky P, Buratowski S.

Mol Cell. 1998 Nov;2(5):663-73.

17.

ADR1-mediated transcriptional activation requires the presence of an intact TFIID complex.

Komarnitsky PB, Klebanow ER, Weil PA, Denis CL.

Mol Cell Biol. 1998 Oct;18(10):5861-7.

18.

ADR1 activation domains contact the histone acetyltransferase GCN5 and the core transcriptional factor TFIIB.

Chiang YC, Komarnitsky P, Chase D, Denis CL.

J Biol Chem. 1996 Dec 13;271(50):32359-65.

Supplemental Content

Loading ...
Support Center